Impedimed (ASX:IPD) Total Payout Ratio: 0.00 (As of Jul. 13, 2026)


What is Impedimed Total Payout Ratio?

Impedimed ASX:IPD +9.09% Total Payout Ratio is 0.00 as of Jul. 13, 2026. The stock has 6 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Impedimed's current Total Payout Ratio is 0.00.

Impedimed Total Payout Ratio Related Terms

Impedimed Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Impedimed's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed Total Payout Ratio Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 2.03 1.39 0.00 0.00

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:IPD vs ABT, SYK, MDT: Total Payout Ratio Comparison

For the Medical Devices subindustry, Impedimed's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impedimed Total Payout Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Impedimed's Total Payout Ratio falls into.


Impedimed Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Impedimed's Total Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -23.237
=0.00

Impedimed's Total Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -12.282
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
Impedimed (ASX:IPD) has a Total Payout Ratio of 0.00 as of Jul. 13, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Impedimed and its competitors.
Is Impedimed's Total Payout Ratio too high?
Impedimed's current Total Payout Ratio is 0.00.
How does Impedimed's Total Payout Ratio compare to ABT and SYK?
Impedimed's Total Payout Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Impedimed and its competitors. Impedimed's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 92.5% below its estimated fair value. The current Total Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Total Payout Ratio is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.